Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | DPP4 | P27487 | 8/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.44 |
| ▸ | FAP | Q12884 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL163395 | 0.98 | ALDH1A1 (0.50) | ALDH1A1DPP4DPP7FAPMEN1 | |
| SCHEMBL28833359 | 0.98 | ALDH1A1 (0.50) | ALDH1A1DPP4DPP7FAPMEN1 | |
| SCHEMBL201078 | 0.98 | ALDH1A1 (0.50) | ALDH1A1DPP4DPP7FAPMEN1 | |
| SCHEMBL15553833 | 0.98 | ALDH1A1 (0.45) | ALDH1A1DPP4DPP7FAPMEN1 | |
| SCHEMBL250459 | 0.98 | ALDH1A1 (0.50) | ALDH1A1DPP4DPP7FAPMEN1 | |
| SCHEMBL173401 | 0.98 | ALDH1A1 (0.50) | ALDH1A1DPP4DPP7FAPMEN1 | |
| SCHEMBL159315 | 0.98 | ALDH1A1 (0.50) | ALDH1A1DPP4DPP7FAPMEN1 | |
| SCHEMBL122347 | 0.98 | ALDH1A1 (0.50) | ALDH1A1DPP4DPP7FAPMEN1 | |
| Hydrochloric Acid SCHEMBL8591556 | 0.98 | ALDH1A1 (0.45) | ALDH1A1DPP4DPP7FAPMEN1 | |
| Methane SCHEMBL8655712 | 0.95 | ALDH1A1 (0.48) | ALDH1A1DPP4DPP7FAPMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1661 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4127157-B1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | ENCODIA INC (US) | 2026-02-11 | — | — | EP | claimed |
| US-20250340595-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1) | BICYCLETX LTD (GB) | 2025-11-06 | — | — | US | claimed |
| US-20250195702-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-06-19 | — | — | US | claimed |
| WO-2025109003-A1 | P-CADHERIN LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-05-30 | — | — | WO | claimed |
| WO-2025054727-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-03-20 | — | — | WO | claimed |
| US-20250059235-A1 | CYCLIC PEPTIDE ANTIVIRAL AGENTS AND METHODS USING SAME | UNIV DREXEL (US) | 2025-02-20 | — | — | US | claimed |
| EP-4499663-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | Provincial Health Services Authority (CA) | 2025-02-05 | — | — | EP | claimed |
| CN-119213011-A | Radiolabeled compounds for in vivo imaging of the Gastrin Releasing Peptide Receptor (GRPR) and treatment of GRPR-related disorders | 省卫生服务机构 | 2024-12-27 | — | — | CN | claimed |
| CN-119158034-A | Bicyclic peptide ligands specific for conjugated protein-4 | 拜斯科技术开发有限公司 | 2024-12-20 | — | — | CN | claimed |
| US-20240391959-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1) | BICYCLETX LIMITED (GB) | 2024-11-28 | — | — | US | claimed |
| EP-0620008-A1 | Use of vip, analogues and fragments thereof for the treatment of neurodegenerative diseases | YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD. (IL) | 1994-10-19 | — | — | EP | claimed |
| WO-1993023426-A1 | MONOMER AND DIMER PEPTIDES, UTILIZATION AS CYTOPROTECTOR AGENTS AND PREPARATION METHOD | SERBIO (FR) | 1993-11-25 | — | — | WO | claimed |
| EP-0373549-B1 | AMINO ACID DERIVATIVES WITH ENZYME-INHIBITING PROPERTIES, PROCESS TO SYNTHETISE THEM, COMPOSITION CONTAINING THEM AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-09-01 | — | — | EP | claimed |
| EP-0552417-A1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-07-28 | — | — | EP | claimed |
| EP-0528312-A2 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-02-24 | — | — | EP | claimed |
| EP-0211744-B1 | PEPTIDIC AMINO-ALCOHOL DERIVATIVES CONTAINING A TETRA-SUBSTITUTED CARBON ATOM, INHIBITORS OF RENIN AND OF ACID PROTEASES, PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS | SANOFI (FR) | 1991-12-04 | — | — | EP | claimed |
| EP-0373549-A2 | Amino acid derivatives with enzyme-inhibiting properties, process to synthetise them, composition containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-06-20 | — | — | EP | claimed |
| EP-0372537-A2 | Urea derivatives of dipeptides with enzyme-inhibiting properties, process to make them, compositions containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-06-13 | — | — | EP | claimed |
| EP-0370383-A2 | Renin-inhibiting dipeptides, process to make them, compositions containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-05-30 | — | — | EP | claimed |
| EP-0100053-B1 | COMPOUNDS HAVING ANGIOTENSIN CONVERTING ENZYME INHIBITORY ACTIVITY AND DIURETIC ACTIVITY | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1987-10-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391959-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1) | TFRC, FTH1, SLC40A1 | ALDH1A1 3280/4885DPP4 2032/4885DPP7 2102/4885 |
| US-20250340595-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1) | TFRC, FTH1, SLC40A1 | ALDH1A1 3280/4885DPP4 2032/4885DPP7 2102/4885 |
| US-20250059235-A1 | CYCLIC PEPTIDE ANTIVIRAL AGENTS AND METHODS USING SAME | ZC3HAV1, VIP, LNPEP | ALDH1A1 4630/4885DPP4 44/4885DPP7 93/4885 |
| US-20250195702-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | GRPR, NPY5R, NPY2R | ALDH1A1 4652/4885DPP4 198/4885DPP7 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.